Non-inferiority trials: why oncologists must remain wary

Mauricio Burotto, Vinay Prasad, Tito Fojo

Resultado de la investigación: Contribución a una revista › Nota › revisión exhaustiva

14 Citas (Scopus)

Acceder al documento

@article{8260daaee76948cd8b464b9153806677,

title = "Non-inferiority trials: why oncologists must remain wary",

author = "Mauricio Burotto and Vinay Prasad and Tito Fojo",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/S1470-2045(15)70129-4",

language = "American English",

volume = "16",

pages = "364--366",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "4",

}

TY - JOUR

T1 - Non-inferiority trials: why oncologists must remain wary

AU - Burotto, Mauricio

AU - Prasad, Vinay

AU - Fojo, Tito

PY - 2015/1/1

Y1 - 2015/1/1

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84933523935&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84933523935&origin=inward

U2 - 10.1016/S1470-2045(15)70129-4

DO - 10.1016/S1470-2045(15)70129-4

M3 - Note

VL - 16

SP - 364

EP - 366

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 4

ER -